公开(公告)号：US20160052988A1

公开(公告)日：2016-02-25

申请号：US14780579

申请日：2014-05-27

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Taiji ASAMI ,  Ayumu NIIDA

IPC: C07K14/605

CPC classification number: C07K14/605 ,  A61K38/00

Abstract: The present invention provides a novel peptide compound having an activating action on GLP-1 receptors and GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a partial sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. P1-Tyr-Aib-Glu-Gly-Thr-al-phaMePhe-Thr-Ser-Asp-Tyr-A11-A12-A13-Leu-Asp-A16-A17-Ala-Gln-A20-Glu-Phe-Val-Lys-Trp-Leu-Leu-Lys-A29 (I) wherein each symbol is as defined herein.

Abstract translation: 本发明提供了对GLP-1受体和GIP受体具有活化作用的新型肽化合物以及肽化合物作为药物的用途。 具体地，提供含有由式（I）表示的部分序列的肽或其盐和包含其的药物。 P1-Tyr-Aib-Glu-Gly-Thr-al-phaMePhe-Thr-Ser-Asp-Tyr-A11-A12-A13-Leu-Asp-A16-A17-Ala-Gln-A20-Glu-Phe-Val- Lys-Trp-Leu-Leu-Lys-A29（I）其中每个符号如本文所定义。

公开(公告)号：US20190202883A1

公开(公告)日：2019-07-04

申请号：US16303975

申请日：2017-05-23

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Taiji ASAMI ,  Ayumu NIIDA

IPC: C07K14/575 ,  A61P3/04 ,  A61P3/10

CPC classification number: C07K14/575 ,  A61K38/00 ,  A61K38/16 ,  A61P3/04 ,  A61P3/10 ,  C12N15/09

Abstract: The present invention relates to a peptide compound that may be useful in the treatment or prophylaxis of obesity, diabetes and the like. More specifically, the present invention relates to a peptide compound represented by the formula (I): P1-Tyr-Aib-Glu-Gly-Thr-α-MePhe-Thr-Ser-Asp-Lys(-Gly-Gly-Gly-Gly-RA10)-A11-A12-Aib-Leu-A15-Lys-Gln-A18-Gln-Iva-Glu-Phe-Val-Arg-His-Leu-Leu-Asn-Lys-Aib-Thr-Arg-Gln-Arg-A35-NH2 wherein each symbol is as defined in the specification, and the treatment or prophylaxis of obesity, diabetes and the like using the peptide compound.

公开(公告)号：US20220135638A1

公开(公告)日：2022-05-05

申请号：US17279266

申请日：2019-09-24

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Hiroshi IMOTO ,  Mari ADACHI ,  Yoko KANEMATSU ,  Taiji ASAMI ,  Ayumu NIIDA ,  Naoki NISHIZAWA ,  Derek Cecil COLE ,  Mack FLINSPACH ,  Nick SCORAH ,  Abhijit Suresh BHAT

IPC: C07K14/575 ,  A61K9/00 ,  A61K9/08 ,  A61K47/02 ,  A61K9/20 ,  A61P1/08

Abstract: The present disclosure provides GIP receptor agonist peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of diabetes, obesity, emesis, or a symptom or condition associated with diabetes, obesity, or emesis. Specifically, a GIP receptor agonist peptide containing a sequence represented by the formula (I) or a salt thereof, and a medicament comprising the same are provided. Formula I: P1-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A341-A32-A33-A34-A35-A36-A37-A38-A39-A40-A41-P2 (SEQ ID NO: 4), or a salt thereof, wherein each symbol is as defined herein, with the proviso that the GIP receptor agonist peptide does not have an amino acid sequence as provided in SEQ ID NOs: 4-569 disclosed in PCT/JP2018/013540.

公开(公告)号：US20210115048A1

公开(公告)日：2021-04-22

申请号：US16608723

申请日：2018-04-26

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shuji KITAMURA ,  Zenichi IKEDA ,  Minoru IKOMA ,  Koji WATANABE ,  Hideki HIROSE ,  Takafumi YUKAWA ,  Sachie MORIMOTO ,  Naoki NISHIZAWA ,  Taiji ASAMI

IPC: C07D487/04 ,  A61P9/04 ,  A61K47/38 ,  A61K31/4184 ,  A61K9/48 ,  A61K9/20

Abstract: The present invention provides a compound or a salt thereof having a calcium-sensing receptor antagonistic activity, and being expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like. The compounds represented by formula (I) or a salt thereof has a calcium-sensing receptor antagonistic activity, and is expected to be useful as an agent for preventing or treating heart failure, pulmonary hypertension, or the like, wherein each symbol is as described in the specification.

公开(公告)号：US20140357552A1

公开(公告)日：2014-12-04

申请号：US14287514

申请日：2014-05-27

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Taiji ASAMI ,  Ayumu NIIDA

IPC: C07K14/605

CPC classification number: C07K14/605 ,  A61K38/00

Abstract: The present invention provides a novel peptide compound having an activating action on GLP-1 receptors and GIP receptors and use of the peptide compound as a medicament. Specifically, a peptide containing a partial sequence represented by the formula (I) or a salt thereof and a medicament comprising the same are provided. (I) P1-Tyr-Aib-Glu-Gly-Thr-αMePhe-Thr-Ser-Asp-Tyr- A11-A12-A13-Leu-Asp-A16-A17-Ala-Gln-A20-Glu- Phe-Val-Lys-Trp-Leu-Leu-Lys-A29 wherein each symbol is as defined herein.

Abstract translation: 本发明提供了对GLP-1受体和GIP受体具有活化作用的新型肽化合物以及肽化合物作为药物的用途。 具体地，提供含有由式（I）表示的部分序列的肽或其盐和包含其的药物。 （I）P1-Tyr-Aib-Glu-Gly-Thr-αMePhe-Thr-Ser-Asp-Tyr-A11-A12-A13-Leu-Asp-A16-A17-Ala-Gln-A20-Glu-Phe-Val -Lys-Trp-Leu-Leu-Lys-A29，其中每个符号如本文所定义。